Lecanemab Drug:
Australia approved Lecanemab drug for early stage Alzheimer’s diseases.
- Lecanemab Drug is a monoclonal antibody drug to treat early stages of Alzheimer’s
- It is designed to slow early Alzheimer’s progression by targeting amyloid proteins in the brain.
- It was developed to tackle the causes of Alzheimer’s disease rather than only relieving the symptoms.
- It uses antibodies to recognise amyloid in the brain and works with the brain’s immune cells to clear amyloid protein build-up from the brains of people living with early-stage Alzheimer’s disease.
- These amyloid protein build-ups are thought to be toxic to brain cells, causing them to get sick and eventually die, leading to the symptoms of Alzheimer’s disease.
- Lecanemab is given to patients intravenously, which means into a vein through a drip bag.
- Recent clinical trials show a 27 per cent reduction in disease progression.
- Issues with Lecanemab Drug: High cost and potential side effects, including brain swelling, limit its accessibility and raise safety concerns.
- Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks.
